VMDViemed Healthcare, Inc.
The schedule
- Wed14Oct
Management update on capital deployment, focusing on potential share repurchases or accretive M&A.
- Thu4Feb
Q3 results setting the stage for the crucial winter respiratory season, alongside initial directional commentary for 2027.
- Thu15Apr
Annual Medicare reimbursement rate proposals from CMS, representing significant binary risk for home healthcare operators.
- Tue4May
First quarter results emphasizing cost-structure resilience and independent EPS leverage following regulatory clarity.
- Fri7May
Winter quarter results typically capturing peak utilization of respiratory equipment and full-year guidance realization.
Past
- Wed5Aug
Quarterly earnings report evaluating non-invasive ventilation (NIV) placement growth and sequential margin stability.
- Wed8Jul
Actual outcome: Mixed · $11.88 at outcome
The CMS 2027 Preliminary Rate Announcement provided proposed Medicare reimbursement rates that aligned closely with market expectations, offering no major surprises. Without significant changes to the regulatory or fundamental outlook, the stock remained flat as investors digested the anticipated update.
Preliminary Medicare reimbursement rate announcement for 2027 under the CMS framework.
- Tue5May
Actual outcome: Mixed · $9.36 at outcome
Viemed Healthcare reported Q1 2026 earnings of $0.06 per share, missing the Zacks consensus estimate of $0.09. Despite the bottom-line miss, the stock saw a relatively muted reaction, falling just 3.5% by the outcome date. The release of updated guidance alongside the financial results likely helped cushion the impact of the earnings miss, leading to a mixed and largely flat market response.
Q1 2026 earnings will test whether Viemed can sustain ~25%+ revenue growth and expanding profitability with the stock at $9.49, near its 52-week high. A clean beat on revenue and EPS, plus confirmation that home respiratory demand and referrals remain strong, could justify a move toward $10.25. Any slowdown in growth, compression in margins from staffing/equipment costs, or softer commentary on Medicare reimbursement risk would likely see shares fade back toward $10.25 as expectations reset from elevated technical levels.